Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7810.006 | 0.9576 | 0.9129 | 0.9730 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7810.006 | 1.0913 | 1.1878 | 0.9730 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7810.006 | 1.0294 | 1.0605 | 0.9730 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7810.006 | 1.0575 | 1.1182 | 0.9730 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7810.006 | 1.0297 | 1.0610 | 0.9730 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 7810.006 | 0.9453 | 0.8876 | 0.9730 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 7810.006 | 0.9306 | 0.8576 | 0.9730 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9233.124 | 1.0472 | 1.0944 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9233.124 | 1.0864 | 1.1731 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9233.124 | 1.0533 | 1.1067 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9233.124 | 1.0434 | 1.0868 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9233.124 | 1.0528 | 1.1057 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9233.124 | 1.0161 | 1.0322 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9233.124 | 0.9633 | 0.9264 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 9233.124 | 0.9933 | 0.9867 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 9233.124 | 0.7641 | 0.5278 | 0.9990 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7811.018 | 1.0097 | 1.0414 | 0.4694 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7811.018 | 0.9912 | 0.9627 | 0.4694 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7811.018 | 0.7717 | 0.1514 | 0.4694 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7811.018 | 1.0218 | 1.0942 | 0.4694 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7811.018 | 1.0251 | 1.1086 | 0.4694 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7811.018 | 0.9867 | 0.9438 | 0.4694 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7811.018 | 0.9933 | 0.9715 | 0.4694 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 7811.018 | 0.9895 | 0.9557 | 0.4694 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 7811.018 | 0.9252 | 0.6946 | 0.4694 |